Company news

Stoke Therapeutics, Inc. news in 2026

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

November 3, 2026

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

October 29, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

October 22, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 16, 2026

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

October 12, 2026

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

October 6, 2026

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

October 5, 2026

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

September 23, 2026

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

September 1, 2026

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

August 5, 2026

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

August 3, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

July 27, 2026

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

July 13, 2026

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

June 30, 2026

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

April 29, 2026

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

April 14, 2026

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

April 6, 2026

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 3, 2026

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy

February 12, 2026

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

February 11, 2026

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

January 19, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 16, 2026

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

January 10, 2026

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026